Biotech Argenica Therapeutics (AGN) has reported no initial safety issues in the sentinel group subject for the third cohort of its ARG-007 brain tissue treatment trial.
This means the company can start dosing the rest of this cohort over the next few days.
This phase one clinical trial, being conducted in Perth, Western Australia, is assessing the safety and tolerability of ARG-007 by incrementally increasing the dose of the drug over four groups of healthy adults. The drug is designed to reduce brain tissue death after strokes.
The first two trial patient groups have so far reported no serious safety issues.
Ahead of dosing the third cohort in the trial, Argenica administered the treatment to one sentinel volunteer, at least 24 hours before the other subjects, to identify any serious safety issues.
Argenica CEO and Managing Director Liz Dallimore said safe dosing of the sentinel subject was “good news”.
“The data from these first two cohorts, as well as the 24-hour sentinel datafrom the third cohort, gives us the confidence to look forward to our phase two trial in stroke patients,” Dr Dallimore said.
“This is a really exciting stage for the company, and we look forward to continuing toprogress the clinical development of ARG-007.”
Once all dosing is complete, the data from this third group will be presented to a Safety Review Committee, which will determine whether Argenica can progress to the dosing of the fourth and final group of subjects, before the company begins the second phase of the trial.
AGN shares were up 7.4 per cent and trading at 58 cents at 3:10 pm AEDT.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。